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Abstract OBJECTIVES: In Spain it is necessary to conduct additional studies to determine 
place in therapy and cost-effectiveness of a drug. The main objective of this study 
is to identify all drug assessments and health technology assessment reports of 
the drugs for gastroenteropancreatic (GEP) neuroendocrine tumors (NET) at 
a national, regional and hospital level and to summarize the efficacy in terms of 
outcome measures, adverse events, economic impact and final recommendations. 
METHODS: A search was made on the GENESIS website for drug evaluation 
reports regarding GwEP NET, including gastrointestinal and bronchopulmonary, 
to identify the drug assessments at a regional and hospital level. 8 reviews at 
regional and hospital level were considered. Two clinical guidelines have been 
reviewed to determine the current management and available treatments. 
RESULTS: Surgery is the main treatment for NETs in different phases of their 
evolution. If there is recurrence there are other possible treatments as chemo-
therapy, somatostatin analogues and new biological agents, also called "targeted 
treatments", that currently have a palliative and symptom control role, since they 
rarely achieve the elimination of the disease themselves. 
CONCLUSIONS: Everolimus and sunitinib are new drugs available for the treat-
ment of GEP NET patients reported to have promising effects in advanced dis-
eases. However, the reports are limited and thus new clinical studies on the impact 
of these drugs on clinical outcome, prognosis, financial burden and feasibility are 
necessary to support further recommendations.
Abbreaviations:
PTCs  -  Pharmacy and Therapeutics committees
GEP - gastroenteropancreatic
NET - neuroendocrine tumors 
AEMPS -  Spanish Agency of Medicines and Health 
Products
WHO - World Health Organization 
ENETS - European Neuroendocrine Tumor Society 
GETNE - Spanish Group of NET
pNET - pancreatic neuroendocrine tumors 
PFS - progression-free survival 
OS - overall survival 
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INTRODUCTION
In European countries during the sales authorization 
process it is not necessary to demonstrate cost-effec-
tiveness or place in therapy of a new drug (Pignati et 
al. 2011); it is only necessary to show a favorable risk-
benefit balance of the new drug to obtain sales authori-
zation (Directive 2004/27/EC).
Hence, it is necessary to conduct further studies to 
determine the place in therapy and cost-effectiveness, 
especially since most drugs available in Spain are 
financed by the public health service. In the UK is the 
NICE, a national government agency, which carries out 
centralized evaluations and makes decision on funding 
(Soto Alvarez, 2009). 
Additionally, due to the decentralized structure of 
the Spanish National Health Service (NHS) the centers 
that evaluate new medications simply provide recom-
mendations that hospitals and prescribers are not 
required to follow. 
Therefore, there is no institution, national or 
regional, that establishes common guidelines for the 
rationalized drug use in the Spanish health system 
based on the criteria of efficiency, effectiveness and 
appropriate use. Consequently, drugs are evaluated and 
selected at a regional level. Regional governments have 
recently published new regional legislation regarding 
rational drug use implementing initial assessment for 
their regions, and have created Pharmacy and Thera-
peutics committees (PTCs), regional committees that 
take mandatory decisions for the entire region. 
Concretely, drugs used in hospitals, including those 
administered to inpatients and outpatients attending 
the hospital for drug administration, and drugs that 
can only be dispensed by the hospital pharmacy ser-
vice, are assessed by PTCs. The PTCs select the drugs 
to be used, generally considering pharmacoeconomic 
criteria and the relative efficiency of drugs compared 
with the alternatives available. Then the selected drugs 
are added to the formulary for each hospital (Fullerton 
& Atherly, 2004).
Once the drug has been selected, the PTC may set 
recommendations and conditions for its use, in the case 
of a drug only used in a specific subgroup or subgroups 
of patients, for its application to entitle clinical benefits, 
and it may state whether the costs have been considered. 
In that case, the use of the drug should be controlled to 
ensure it meets the established criteria.
Therefore, the main objective of this study is to 
identify all drug assessments and health technology 
assessment reports of the drugs used for gastroentero-
pancreatic (GEP) neuroendocrine tumors (NET) at a 
national, regional and hospital level and to summarize 
the efficacy in terms of outcome measures, adverse 
events, economic impact and final recommendations. 
The secondary objective is to determine the current 
management and available treatments for GEP NET.
METHODS
A search was made on the GENESIS website (GENESIS 
website) for drug evaluation reports regarding GEP 
NET, including gastrointestinal and bronchopulmo-
nary, to identify the drug assessments at a regional and 
hospital level. There were no health technology assess-
ment reports for GEP NET at national level.
The reports included in this analysis assess the 
current treatment of GEP NET. These correspond to 
8 reviews at regional and hospital (CatSalut website. 
Everolimus report; CatSalut website. Everolimus opin-
ion; CatSalut website. Sunitinib report; CatSalut web-
site. Sunitinib opinion; GENESIS website. Sunitinib 
report; ICO website. Everolimus & Sunitinib report; 
SEOM website. Everolimus report). 
The following parameters were considered for each 
of the reports: country, region and agency or hospital 
were the report has been written, drug name, active 
ingredient, presentations, posology and administra-
tion form, Spanish Agency of Medicines and Health 
Products (AEMPS) authorization date, pharmaceutical 
company that commercializes the drug, price, report 
initiation date, report publication date, disease area, 
indication evaluated, ATC code, RTCs methodology, 
RCTs comparators, primary outcomes measures, sec-
ondary outcomes measures, efficacy measures results, 
adverse events, conclusions (efficacy, safety and costs), 
recommendations and web link to the report. 
Moreover, in order to determine the current man-
agement and available treatments for GEP NET, two 
clinical guidelines have been reviewed (Matos & Cap-
devilla, 2015; GTNE website).
RESULTS
Current situation of GEP NET in Spain
Description of the disease
GEP NET constitute a heterogeneous group of tumors 
with their origin in neuroendocrine cells of the embry-
ological gut. Most commonly, the primary lesion is 
located in the gastric mucosa, the small and large intes-
tine, the rectum and pancreas. Most NETs are sporadic 
and do not have a known cause or risk factors. However, 
in some cases aggregates can appear in families, giving 
rise to hereditary syndromes, when there are certain 
germ-line mutations that can be transmitted in suc-
cessive generations. The most currently accepted clas-
sification of the GEP NET is based on that established 
in 2010 by the World Health Organization (WHO) 
improved by the criteria and guidelines proposed by the 
European Neuroendocrine Tumor Society (ENETS). It 
distinguishes in a primary way between well differen-
tiated and poorly differentiated tumors, to then make 
a more precise classification by means of a system of 
gradation (G1, G2, G3) in stages, using proliferation 
markers and anatomopathological criteria (Table 1).
Diagnostic process
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The histological diagnosis is mandatory to establish the 
diagnosis of NET and is usually obtained by surgery, 
endoscopic biopsy or liver biopsy guided by ultrasound 
or CT. The diagnostic process must include the fol-
lowing steps: 1) Adequate anatomopathological iden-
tification; 2) Hormone characterization of the tumor, 
clinical and biochemical; 3) Imaging studies to locate 
the primary tumor, assess its resectability and establish 
the extent of metastatic disease; 4) MEN1 syndrome 
identification. The Spanish Group of NET (GETNE) 
in its clinical guideline has developed an algorithm of 
diagnosis (Figure 1).
Current management of GEP NET
Surgery is the main treatment of NETs in different 
phases of their evolution. In early stages, complete 
tumor resection is performed with curative intent; in 
Tab. 1. GEP NET classification
Grade of 
malignanacy GEP NET ENETS GEP NET WHO
G1 (low) <2 mitosis/10 HPF<3% Ki-67
<2 mitosis/10 HPF
≤2% Ki-67
G2 (medium) 2-20 mitosis/10 HPF3%-20% Ki-67
2-20 mitosis/10 HPF
3%-20% Ki-67
G3 (high) >20 mitosis/10 HPF>20% Ki-67
>20 mitosis/10 HPF
>20% Ki-67
10 HPF: 10 high power fields = 2 mm2, at least 40 fields (at ×40 
magnification) evaluated in areas of highest mitotic density. 
more advanced cases, surgery can be carried out with 
cytoreductive intention or palliation of symptoms. If 
there is recurrence there are other possible treatments 
as chemotherapy, somatostatin analogues and new bio-
logical agents, also called "targeted treatments", that 
currently have a palliative and symptom control role, 
since they rarely achieve the elimination of the disease 
themselves. In many patients, especially if they have 
metastases, it will be necessary to use several of these 
treatments throughout the disease.
Treatment algorithm for GEP NET
The current therapeutic goal in GEP NET is to cure the 
disease by using surgery and if it is not possible, to palli-
ate the symptoms. Thus, the available drugs are focused 
on extending survival and maintain a good quality of 
life.
Depending on the NET type there are two main 
algorithms of treatment. 
The first algorithm corresponds to the treatment 
algorithm for patients with pancreatic NET (Figure 2). 
At first, the treatment depends on whether the NET is 
resectable or not. If it is resectable, a surgical resection 
is conducted, and, in case of recurrence, a re-resection 
is recommended. When the NET is not resectable, the 
treatment depends on whether the tumor is a function-
ing or a non-functioning tumor. If it is a non-function-
ing tumor, the treatment depends on the tumor stage 
and can be treated with targeted therapy, chemotherapy 
or with radionuclides. If it is a functioning tumor, the 
first treatment line is symptomatic treatment of hor-
Fig. 1. GEP NET diagnostic algorithm
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monal secretion, and if there is recurrence, the treat-
ment is the same as if it were a non-functioning tumor. 
The second algorithm corresponds to the treatment 
algorithm for patients with carcinoid NET (Figure 3). 
At first, the treatment depends on whether the NET is 
resectable or not. If it is resectable, a surgical resection 
is conducted, and in case of recurrence a re-resection 
is recommended. When the NET is not resectable, 
the treatment depends on whether there is carcinoid 
syndrome or not. If there is a NET with carcinoid syn-
drome the first line of treatment is with somatostatin 
analogues combined with a possible cytoreductive sur-
gery. If there is no carcinoid syndrome the first line of 
treatment is a treatment with Octreotide LAR. If after 
these treatments there is tumor recurrence, the treat-
ment depends on the tumor stage and can be treated 
with targeted therapy, chemotherapy, interferon alpha 
or with radionuclides. 
Drug assessment 
The reports included in this analysis assess the current 
treatment of GEP NET. These correspond to 8 reviews 
at regional and hospital level (Table 2). 
1) Everolimus (afinitor®)
Four reports, one from the SEOM in 2016, two from 
the CAMHDA in 2012 and one from the ICO in 2011, 
have evaluated everolimus as treatment for patients 
with non-functioning, unresectable or metastatic, in 
progression, WHO grade 1/2 NETs of gastrointestinal 
Fig. 2. Treatment algorithm for patients with pancreatic NET
Fig. 3. Treatment algorithm for treatment of patients with carcinoid NET
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and bronchopulmonary origin (Table 3). Considering 
the efficacy and safety results, and according to the 
report conclusions, everolimus has demonstrated sig-
nificant differences in terms of progression-free sur-
vival (PFS) in the comparison with placebo. This result 
was supported by two centralized committees with very 
similar results. The average overall survival (OS) had 
not been achieved at the time of the analysis and no 
significant differences between both treatment groups 
were observed. No data on the quality of life is available 
in this study. 
The therapeutic positioning recommendations 
suggest treatment with everolimus in patients with 
advanced or unresectable NETs of bronchopulmonary 
and gastrointestinal origin, well-moderately differenti-
ated, WHO grades 1 and 2, non-functioning and pro-
gressively documented by RECIST criteria in the last 6 
months of follow-up.
2) Sunitinib (sutent®)
Four reports, one from the Genesis Group in 2013, two 
from the CAMHDA in 2012 and one from the ICO in 
2011, have evaluated sunitinib as a treatment for pan-
creatic neuroendocrine tumors (pNET), well differen-
tiated, non-resectable or metastatic, in adult patients 
with progressive disease (Table 4). Considering the 
efficacy and safety results and according to the report 
conclusions, sunitinib has demonstrated significant 
Tab. 2. Drugs assessed in GEP NET
Name of the drug Active substance Pharmaceutical Laboratory
Authorization 
date Drug assessment reports
AFINITOR® 1 mg/ml 
concentrate for solution 
for infusion
Everolimus Novartis Europharm Limited 17/09/2009
 • 2016 – SEOM
 • 2012 – CAMHDA (1)
 • 2012 – CAMHDA (2)
 • 2011 – ICO
SUTENT® (200;400) u 
powder for concentrate 
for solution for infusion
Sunitinib Pfi zer Limited 29/09/2009
 • 2013– Genesis Group
 • 2012 – CAMHDA (1)
 • 2012 – CAMHDA (2)
 • 2011 – ICO
Tab. 3. Everolimus assessment results
Indication Posology and administration
Parameters 
evaluated
Therapeutic positioning
Conclusions Recommendations
Treatment of 
patients with 
non-functioning, 
unresectable 
or metastatic, 
in progression, 
WHO grade 1/2 
neuroendocrine 
tumors of  
gastrointestinal 
and 
bronchopulmonary 
origin.
• POSOLOGY
- Everolimus: 10 mg 
once a day, always 
at the same time.
Dose modifi cations 
can be applied 
based on safety 
and individual 
tolerability. The 
recommended 
modifi ed dose is 5 
mg per day.
• ADMINISTRATION 
FORM 
Oral route
Effi  cacy According to the study that 
evaluated the effi  cacy of 
everolimus, this therapy has 
demonstrated signifi cant 
diff erences in terms of PFS in 
the comparison with placebo. 
This result was supported by 
two centralized committees with 
very similar results. The average 
OS had not been achieved at 
the time of the analysis and no 
signifi cant diff erences between 
both treatment groups were 
observed. No data on the quality 
of life in this study is available.
The global cost per treatment 
with everolimus is estimated 
at 40.095,25 €/year, which 
involves an incremental cost-
eff ectiveness +67.9624 €/year 
with regards to placebo. In 
Catalonia, it is estimated that the 
annual incidence of pNET could 
be 27 new patients per year. 
Assuming a 12 month treatment 
duration, the additional annual 
budgetary impact of treating 27 
patients with everolimus will be 
1.082.272 €.
Following the 
recommendations and 
approvals of the diff erent 
regulatory authorities based on 
the results of the RADIANT-4 
prospective and randomized 
phase III study, everolimus 
should be recommended for 
the treatment of patients with 
advanced or unresectable 
NETs of bronchopulmonary 
and gastrointestinal origin, 
well-moderately diff erentiated, 
WHO grades 1 and 2, non-
functioning and progressively 
documented by RECIST 
criteria in the last 6 months of 
follow-up.
•  Progression-free 
survival (PFS)
•  Other variables: 
Overall survival 
(OS), Security, 
Overall response 
rate (ORR), 
Disease control 
rate (DCR), 
Duration of the 
response.
Safety
Stomatitis, 
diarrhea, asthenia, 
infections, rash, 
peripheral edema 
and nausea.
Cost
Global treatment 
cost
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differences in terms of PFS and OS in the comparison 
with placebo. In global, the differences obtained in the 
variables PFS and OS can be considered clinically rel-
evant results that confirm the superior efficacy of suni-
tinib. The therapeutic positioning recommendations 
that suggest treatment with everolimus in patients with 
pNETs are limited, and sunitinib has become a new 
option after failure or relapse. Sunitinib is considered a 
treatment option in adult patients with well differenti-
ated, unresectable or metastatic pNET tumor, with:
1) Progression of the disease after previous treatment; 
2) ECOG ≤ 1; 3) Disease progression documented 
radiographically; and 4) Renal, hematological and 
hepatic normal function.
DISCUSSION 
Clinical guidelines 
The therapeutic objective in gastroenteropancreatic 
neuroendocrine tumors (GEP NET) is focused in cure 
by surgery, and if this is not possible, in palliation. This 
palliation is based on three goals: control of disease, 
extension of survival and maintenance of quality of life. 
During the last decade new drugs active in advanced 
NETs have been found, as a consequence of the more 
extensive knowledge of the biology of these neoplasms, 
this advances allow us to be optimistic about the thera-
peutic options to be used in these patients. Nonethe-
less, there is still not enough evidence to make strict 
recommendations.
It remains to be determined whether somatostatin 
analogues should be used in monotherapy or associ-
ated with antiangiogenic agents or mTOR inhibitors. It 
is also unknown which is the optimal sequence of drugs 
in NET, if an antiangiogenic and then an mTOR inhibi-
tor should be used first, or vice versa.
Further, it remains unknown which is the most 
active antiangiogenic agent, and whether biological 
agents or chemotherapy should be used first, despite all 
the information provided by clinical guidelines. 
Drug assessment
In general, comparators used in the evaluations are con-
sidered adequate. However, the combination of strepto-
zocin with doxorubicin or 5-FU would be considered 
also valid options, with rates of response of 69% vs. 45% 
achieved according to the randomized trial of Moertel 
et al. (1992).
The use of PFS is considered adequate since it is the 
recommended variable in efficacy studies where a delay 
in the progression in absence of radiological tumor 
responses is expected.
The use of OS is not considered adequate, except in 
highly refractory cases or when the expected survival 
is limited.
Follow-up periods of the studies for both treatments 
(everolimus and sunitinib) appear to be short in con-
tinuous treatments. Therefore, it would be necessary 
to extend the follow-up period in order to obtain long-
term efficacy data.
Tab. 4. Sunitinib assessment results
Indication Posology and administration Parameters evaluated
Therapeutic positioning
Conclusions Recommendations
Treatment of 
pancreatic 
neuroendocrine 
tumors 
(pNET), well  
diff erentiated, 
non- resectable 
or metastatic, in 
adult patients 
with progressive 
disease
• POSOLOGY
- Sunitinib: 37.5 mg 
orally once daily, 
with no scheduled 
rest period. Dose 
modifi cations can 
be applied with 
variations of 12.5 
mg based on safety 
and individual 
tolerability.
• ADMINISTRATION 
FORM 
Oral route
Effi  cacy According to the study that 
evaluated the effi  cacy of 
sunitinib, this therapy has 
demonstrated signifi cant 
diff erences in terms of PFS 
and OS in the comparison 
with placebo. In global, the 
diff erences obtained in the 
variables PFS and OS can 
be considered clinically 
relevant results that confi rm 
the superiority in effi  cacy of 
sunitinib.
The global cost per treatment 
with sunitinib is estimated at 
45.897,6 €, which involves an 
incremental cost- eff ectiveness 
+93.313 €/year with regards to 
placebo. Taking into account 
that in a hospital 1 or 2 new 
patients per year might be 
candidates to receive treatment 
with sunitinib, a budget impact 
between 93.313€ and 186.626€ is 
estimated assuming a treatment 
for 12 months.
Because the eff ective 
treatment options available 
to patients with pancreatic 
neuroendocrine tumors 
are so limited, sunitinib has 
become a new option after 
failure or relapse. Sunitinib is 
considered a treatment option 
in adult patients with well 
diff erentiated, unresectable 
or metastatic pancreatic 
neuroendocrine tumor, with:
•  Progression of the disease 
after previous treatment
•  ECOG ≤1
•  Disease progression 
documented radiographically
•  Renal, hematological and 
hepatic normal function
•  Progression-free 
survival (PFS)
•  Other variables: 
Overall survival (OS), 
Objective response 
rate (ORR), Duration 
of the response, 
Security
Safety
Anorexia, dysgeus la, 
hypertension, fatigue, 
gastrointestinal 
disorders, skin 
discoloration and 
palmoplantar 
erythrodysesthesia 
syndrome.
Cost
Global treatment cost
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Due to the limited experience on the effectiveness of 
everolimus and sunitinib in naive patients, it is neces-
sary to conduct a study in order to draw conclusions 
about this subgroup.
CONCLUSIONS
Everolimus and sunitinib are new drugs available for the 
treatment of GEP NET patients reported to have prom-
ising effects in advanced diseases. However, the reports 
are limited and thus new randomised, controlled clini-
cal studies on the impact of these drugs on clinical out-
come, prognosis, financial burden and feasibility are 
necessary to support further recommendations.
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